Entrada Therapeutics Inc (TRDA)

$5.27 +0.02 (0.38%)
Market Cap 199.69M
Revenue (ttm) 210.78M
Net Income (ttm) 65.63M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 31.14%
Debt to Equity Ratio 0.00
Volume 345,700
Avg Vol 184,228
Day's Range N/A - N/A
Shares Out 38.04M
Stochastic %K 32%
Beta -0.12
Analysts Strong Sell
Price Target $18.50

Company Profile

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. The company's EEV platform develops products based on oligonucleotide, enzyme, and antibody-conjugated EEV peptides. Its therapeutic candidates, which include ENTR-601-44 that is in Phase 1 clinical trial for the treatment of Duchenne muscular dystrophy; and VX-670, which is in Phase 1/2 clinical trial for the treatment of...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 520 9158
Address:
One Design Center Place, Suite 17- 500, Boston, United States
maizeblue22
maizeblue22 Aug. 13 at 6:17 PM
$TRDA is developing a platform technology that has high impact potential. A lot of people in the biotech ecosystem are excited about it and have been for 5y. Co is also trading under cash. Why is this down so much?
1 · Reply
Tradr1205
Tradr1205 Aug. 6 at 4:42 PM
$TRDA I bought another large chunck this morning. This stock is crazy undervalued! Too much upside to pass up!
1 · Reply
gilheydari
gilheydari Aug. 6 at 3:12 PM
$TRDA I guess manipulated badly, looks at volume and percentage drop!
0 · Reply
VinWeezel
VinWeezel Aug. 6 at 3:09 PM
$TRDA now a market cap of 194 million. 350 million in cash. Thoughts?
1 · Reply
d_risk
d_risk Aug. 6 at 1:30 PM
$TRDA - Entrada Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors TRDA’s 2025 10-Q risk update highlights extended cash runway to mid-2025, heavy reliance on lead candidate ENTR-601-44, expanded regulatory, IP, and commercialization risks, intensified talent retention challenges amid workforce cuts, increased legal and cybersecurity exposures, and new risks from strategic transactions, tax law changes, and public company compliance burdens. #Biotechnology #Cybersecurity #TalentRetention #RegulatoryRisk #DrugDevelopment 🟢 Added 🟠 Removed https://d-risk.ai/TRDA/10-Q/2025-08-06
1 · Reply
VinWeezel
VinWeezel Aug. 6 at 12:17 PM
$TRDA https://www.stocktitan.net/news/TRDA/entrada-therapeutics-reports-second-quarter-2025-financial-nyq4651jnxvr.html
0 · Reply
outlawinvestor1
outlawinvestor1 Jul. 26 at 1:49 PM
$TRDA I’ve started a position at these levels. Clinical stage biotech with minimal spend, partnership and licensing revenues from a strong rare disease biotech player trading below cash. Another potential headwind that seems to have missed entrada so far is that they’re delivering a gene therapy without the potential/perceived harm of AAV viral vectors (eg $SRPT). Will buy/build more, if it dips further. My only critique is that they don’t give guidance on future trial readouts in their corporate pdf so not sure when the catalyst events will take place.
0 · Reply
Tradr1205
Tradr1205 Jul. 15 at 4:45 PM
$TRDA Bought some more. This is over-blown. Reversal forthcoming
2 · Reply
VinWeezel
VinWeezel Jul. 15 at 3:59 PM
$TRDA prolly more 5am ventures selling-Market selling tiny bits into 0 volume. Downward pressure. Not ideal days here.
2 · Reply
Tradr1205
Tradr1205 Jul. 11 at 6:01 AM
$TRDA Bought a nice chunck before the market closed. I think we're trading back above $7 in the am
0 · Reply
Latest News on TRDA
Entrada Therapeutics Reports Second Quarter 2025 Financial Results

Aug 6, 2025, 7:00 AM EDT - 10 days ago

Entrada Therapeutics Reports Second Quarter 2025 Financial Results

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

Jun 3, 2025, 7:00 AM EDT - 2 months ago

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

BIIB

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 2, 2025, 4:30 PM EDT - 2 months ago

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

May 28, 2025, 7:00 AM EDT - 2 months ago

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

Entrada Therapeutics Reports First Quarter 2025 Financial Results

May 8, 2025, 7:00 AM EDT - 3 months ago

Entrada Therapeutics Reports First Quarter 2025 Financial Results

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

Mar 24, 2025, 7:00 AM EDT - 5 months ago

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 27, 2025, 7:00 AM EST - 6 months ago

Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44

Feb 24, 2025, 7:00 AM EST - 6 months ago

Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44

Entrada Therapeutics: Cash-Rich Innovator With Asymmetric Upside

Feb 19, 2025, 11:31 AM EST - 6 months ago

Entrada Therapeutics: Cash-Rich Innovator With Asymmetric Upside

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy

Feb 3, 2025, 7:00 AM EST - 6 months ago

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy

Azenta Announces the Election of Dipal Doshi to its Board of Directors

Jan 30, 2025, 4:05 PM EST - 7 months ago

Azenta Announces the Election of Dipal Doshi to its Board of Directors

AZTA

Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 18, 2024, 7:00 AM EST - 8 months ago

Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society

Oct 9, 2024, 7:00 AM EDT - 11 months ago

Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society

Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development

Sep 24, 2024, 7:00 AM EDT - 11 months ago

Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development

āshibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of Directors

Sep 17, 2024, 8:30 AM EDT - 11 months ago

āshibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of Directors

Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program

Sep 6, 2024, 7:00 AM EDT - 1 year ago

Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program

Entrada Therapeutics Announces $100 Million Registered Direct Offering

Jun 24, 2024, 7:15 AM EDT - 1 year ago

Entrada Therapeutics Announces $100 Million Registered Direct Offering

Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy

Jun 24, 2024, 6:00 AM EDT - 1 year ago

Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy

Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference

Jun 3, 2024, 7:00 AM EDT - 1 year ago

Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference

Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 16, 2024, 7:00 AM EDT - 1 year ago

Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Entrada Therapeutics Reports First Quarter 2024 Financial Results

May 7, 2024, 7:00 AM EDT - 1 year ago

Entrada Therapeutics Reports First Quarter 2024 Financial Results

Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 13, 2024, 7:00 AM EDT - 1 year ago

Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Entrada Therapeutics to Present at Upcoming Investor Conferences

Feb 7, 2024, 7:00 AM EST - 1 year ago

Entrada Therapeutics to Present at Upcoming Investor Conferences

Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy

Nov 22, 2023, 7:00 AM EST - 1 year ago

Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy

Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy

Sep 21, 2023, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy

Entrada Therapeutics Appoints Gina Chapman to its Board of Directors

Aug 10, 2023, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Appoints Gina Chapman to its Board of Directors

Entrada Therapeutics Reports Second Quarter 2023 Financial Results

Aug 8, 2023, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Reports Second Quarter 2023 Financial Results

Entrada Therapeutics: Early Stage But Interesting

Aug 3, 2023, 6:39 PM EDT - 2 years ago

Entrada Therapeutics: Early Stage But Interesting

Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare Conference

Jun 6, 2023, 7:00 AM EDT - 2 years ago

Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare Conference

Entrada Therapeutics Reports First Quarter 2023 Financial Results

May 10, 2023, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Reports First Quarter 2023 Financial Results

Entrada Therapeutics Appoints Dr. Bernhardt Zeiher to its Board of Directors

Apr 4, 2023, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Appoints Dr. Bernhardt Zeiher to its Board of Directors

Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease Conference

Mar 29, 2023, 7:00 AM EDT - 2 years ago

Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease Conference

Entrada Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

Mar 6, 2023, 7:00 AM EST - 2 years ago

Entrada Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

Entrada Therapeutics to Participate in Cowen 43rd Annual Health Care Conference

Feb 27, 2023, 7:00 AM EST - 2 years ago

Entrada Therapeutics to Participate in Cowen 43rd Annual Health Care Conference

Entrada Therapeutics Announces Clinical Hold on IND Application for ENTR-601-44 in Duchenne Muscular Dystrophy

Dec 19, 2022, 4:30 PM EST - 2 years ago

Entrada Therapeutics Announces Clinical Hold on IND Application for ENTR-601-44 in Duchenne Muscular Dystrophy

Entrada Therapeutics shares jump on collaboration with Vertex

Dec 8, 2022, 8:24 AM EST - 2 years ago

Entrada Therapeutics shares jump on collaboration with Vertex

Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1)

Dec 8, 2022, 7:00 AM EST - 2 years ago

Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1)

VRTX

Entrada Therapeutics Reports Third Quarter 2022 Financial Results

Nov 7, 2022, 7:00 AM EST - 3 years ago

Entrada Therapeutics Reports Third Quarter 2022 Financial Results

Entrada Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

Aug 30, 2022, 7:00 AM EDT - 3 years ago

Entrada Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

Entrada Therapeutics Reports Second Quarter 2022 Financial Results

Aug 11, 2022, 7:00 AM EDT - 3 years ago

Entrada Therapeutics Reports Second Quarter 2022 Financial Results

Entrada Therapeutics Appoints Karla MacDonald as Chief Corporate Affairs Officer

Jul 19, 2022, 7:00 AM EDT - 3 years ago

Entrada Therapeutics Appoints Karla MacDonald as Chief Corporate Affairs Officer

Entrada Therapeutics to Present at William Blair Biotech Focus Conference

Jul 6, 2022, 7:00 AM EDT - 3 years ago

Entrada Therapeutics to Present at William Blair Biotech Focus Conference

Entrada Therapeutics to Present at Goldman Sachs Global Healthcare Conference

Jun 1, 2022, 7:00 AM EDT - 3 years ago

Entrada Therapeutics to Present at Goldman Sachs Global Healthcare Conference

Entrada Therapeutics Reports First Quarter 2022 Financial Results

May 12, 2022, 7:00 AM EDT - 3 years ago

Entrada Therapeutics Reports First Quarter 2022 Financial Results

Entrada Therapeutics Presents New Data Supporting its Growing Pipeline of Endosomal Escape Vehicle (EEV™) Therapeutics at TIDES USA 2022

May 11, 2022, 9:30 AM EDT - 3 years ago

Entrada Therapeutics Presents New Data Supporting its Growing Pipeline of Endosomal Escape Vehicle (EEV™) Therapeutics at TIDES USA 2022

5 Short Squeeze Candidates To Watch: Aterian And Newegg Remain In Top Two Positions, Cannabis Company Joins List Week Of 4/20

Apr 18, 2022, 9:48 AM EDT - 3 years ago

5 Short Squeeze Candidates To Watch: Aterian And Newegg Remain In Top Two Positions, Cannabis Company Joins List Week Of 4/20

ATER NEGG BEEM

Entrada Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

Mar 15, 2022, 7:00 AM EDT - 3 years ago

Entrada Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

maizeblue22
maizeblue22 Aug. 13 at 6:17 PM
$TRDA is developing a platform technology that has high impact potential. A lot of people in the biotech ecosystem are excited about it and have been for 5y. Co is also trading under cash. Why is this down so much?
1 · Reply
Tradr1205
Tradr1205 Aug. 6 at 4:42 PM
$TRDA I bought another large chunck this morning. This stock is crazy undervalued! Too much upside to pass up!
1 · Reply
gilheydari
gilheydari Aug. 6 at 3:12 PM
$TRDA I guess manipulated badly, looks at volume and percentage drop!
0 · Reply
VinWeezel
VinWeezel Aug. 6 at 3:09 PM
$TRDA now a market cap of 194 million. 350 million in cash. Thoughts?
1 · Reply
d_risk
d_risk Aug. 6 at 1:30 PM
$TRDA - Entrada Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors TRDA’s 2025 10-Q risk update highlights extended cash runway to mid-2025, heavy reliance on lead candidate ENTR-601-44, expanded regulatory, IP, and commercialization risks, intensified talent retention challenges amid workforce cuts, increased legal and cybersecurity exposures, and new risks from strategic transactions, tax law changes, and public company compliance burdens. #Biotechnology #Cybersecurity #TalentRetention #RegulatoryRisk #DrugDevelopment 🟢 Added 🟠 Removed https://d-risk.ai/TRDA/10-Q/2025-08-06
1 · Reply
VinWeezel
VinWeezel Aug. 6 at 12:17 PM
$TRDA https://www.stocktitan.net/news/TRDA/entrada-therapeutics-reports-second-quarter-2025-financial-nyq4651jnxvr.html
0 · Reply
outlawinvestor1
outlawinvestor1 Jul. 26 at 1:49 PM
$TRDA I’ve started a position at these levels. Clinical stage biotech with minimal spend, partnership and licensing revenues from a strong rare disease biotech player trading below cash. Another potential headwind that seems to have missed entrada so far is that they’re delivering a gene therapy without the potential/perceived harm of AAV viral vectors (eg $SRPT). Will buy/build more, if it dips further. My only critique is that they don’t give guidance on future trial readouts in their corporate pdf so not sure when the catalyst events will take place.
0 · Reply
Tradr1205
Tradr1205 Jul. 15 at 4:45 PM
$TRDA Bought some more. This is over-blown. Reversal forthcoming
2 · Reply
VinWeezel
VinWeezel Jul. 15 at 3:59 PM
$TRDA prolly more 5am ventures selling-Market selling tiny bits into 0 volume. Downward pressure. Not ideal days here.
2 · Reply
Tradr1205
Tradr1205 Jul. 11 at 6:01 AM
$TRDA Bought a nice chunck before the market closed. I think we're trading back above $7 in the am
0 · Reply
Goosem4n
Goosem4n Jul. 10 at 5:48 PM
$TRDA anyone shorting this hasn't checked the balance sheet.
1 · Reply
VinWeezel
VinWeezel Jul. 10 at 12:24 AM
$TRDA anyone here at all? Turda rockets or no?
1 · Reply
VinWeezel
VinWeezel Jun. 27 at 8:33 PM
$TRDA 400,000 shares traded ah and no price movement
0 · Reply
VinWeezel
VinWeezel Jun. 25 at 4:46 PM
$TRDA https://www.tradingview.com/news/tradingview:da469c2620fe4:0-entrada-therapeutics-director-kim-peter-s-acquires-25-000-shares/ this was repoted again last week cause he filed wrong. He bought 25,000 two days in a row. But how did he pay 14 in may when price was 9? This guy is literally a genius. I’m adding.
1 · Reply
valueforme
valueforme Jun. 17 at 1:19 AM
$TRDA Forgotten stock. Depending on what DYN has to say tomorrow, I might consider buying here
1 · Reply
VinWeezel
VinWeezel May. 28 at 5:54 PM
$TRDA https://www.stocktitan.net/news/TRDA/entrada-therapeutics-receives-authorization-in-the-european-union-to-oko6tip1t5oz.html
0 · Reply
VinWeezel
VinWeezel May. 25 at 3:42 PM
$TRDA 16 this shortened week
0 · Reply
xrichsayzx88
xrichsayzx88 May. 20 at 6:33 PM
$TRDA $10
0 · Reply
JarvisFlow
JarvisFlow May. 20 at 11:00 AM
HC Wainwright & Co. updates rating for Entrada Therapeutics ( $TRDA ) to Buy, target set at 20.
0 · Reply
VinWeezel
VinWeezel May. 18 at 11:54 AM
$TRDA lets go to 16 this week 😬
0 · Reply
Uneducated_Trader
Uneducated_Trader May. 15 at 1:46 PM
$TRDA
0 · Reply
Armonica423
Armonica423 May. 10 at 5:20 PM
$TRDA Big exposure for CYDY at 3 oncology conferences this coming week, do your dd research
0 · Reply